Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,303.68 -17.73 (-0.33%) Dow
39,689.43 -183.56 (-0.46%) Nasdaq
16,776.03 -56.59 (-0.34%) Bitcoin USD
69,645.73 -206.23 (-0.30%) CMC Crypto 200
1,515.70 -10.72 (-0.70%)
PFE Jun 2024 24.000 call
| Previous close | 4.75 |
| Open | 5.50 |
| Bid | 5.40 |
| Ask | 5.45 |
| Strike | 24.00 |
| Expiry date | 2024-06-21 |
| Day's range | 5.42 - 5.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 160 |
ReutersPfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027
The cost cuts are the latest move by the company to respond to slumping demand for its COVID-19 products after they powered it to report record revenues in 2021 and 2022. Pfizer's shares were up 2.6% at $29.3 in afternoon trading.
BenzingaGSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid
BenzingaPfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights. The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx. Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs. Puma Biotechnology Inc (
